Aim. Тo determine the serum level of EMAP-II as a marker of endothelial dysfunction in type 1 diabetic patients with microangiopathy, to study of the association of arterial hypertension and the level of this factor, its relationship with the endothelium-dependent dilatation and other risk factors for cardiovascular disease.
Materials and methods. We examined 23 type 1 diabetic patientwith microangiopathy and arterial hypertension, 10 type 1 diabetic patient with microangiopathy without hypertension and 28 healthy control subjects. Serum levels of EMAP-II were determined by immunoenzyme assay. Endothelium-dependent dilatation was estimated by Celermajers metod. The data were presented as means±SD. Statistical analysis was performed using the t-Student, Spearman's rank correlation coefficient, multiple regression analysis.
Results. We found an increased serum level of EMAP-II in type 1 diabetic patients with microangiopathy and arterial hypertension compared to control group (5,23±1,66ng/ml and 1,25±0,76 ng/ml respectively, р<0,01), and in type 1 diabetic patients with microangiopathy and arterial hypertension compared to group of diabetic patients without hypertension (5,23±1,66ng/ml and 3,63±1,9ng/ml respectively, р<0,01). Also, the level of EMAP-II correlated with key markers of carbohydrate and lipid metabolism, and inversely correlated with endothelium-dependent dilatation (p<0,05). Significant factors that affect on the serum level of EMAR-II in type 1 diabetes patients with microangiopathy and arterial hypertension were HbA1c, total cholesterol and triglycerides, also systolic and diastolic blood pressure, and in non-hypertensive patients - HbA1c.
Conclusion. The revealed changes of EMAP-II serum levels could reflect an endothelial dysfunction in patients with type 1 diabetes with microangiopathy and arterial hypertension. Arterial hypertension, hyperglycemia, dyslipidemia appear to be significant contributing factor to the elevation of EMAP-II.

Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes and hypertention